Related Experiment Videos
[Current possibilities in the therapy of iron overload]
1Ustav hematologie a krevní transfuze, Praha.
Vnitrni Lekarstvi
|September 1, 1994
Summary
Chronic iron overload causes organ damage. Oral iron chelators like Deferiprone show promise but have serious side effects, necessitating research into safer alternatives for treating iron overload.
Area of Science:
- * Pharmacology
- * Medicinal Chemistry
- * Clinical Medicine
Context:
- * Chronic iron accumulation leads to significant tissue damage, cardiac, and hepatic failure.
- * Current standard treatment, desferrioxamine (Desferal), requires parenteral administration.
- * Need for orally active iron chelators with efficacy comparable to desferrioxamine.
Purpose:
- * To review the development and challenges of orally active iron chelators.
- * To highlight hydroxypyridones, particularly 1,2-dimethyl-3-hydroxypyrid-4-one (Deferiprone), as promising candidates.
- * To discuss ongoing research into alternative oral iron chelators.
Summary:
- * Desferrioxamine is the only approved chelator, but requires infusion.
- * Oral hydroxypyridones, like Deferiprone, demonstrate effective iron excretion.
- * Deferiprone's clinical use is limited by adverse effects such as agranulocytosis.
- * Other oral chelators like PIH and HBED are under investigation.
Impact:
- * Development of safe, inexpensive, orally effective iron chelators is crucial.
- * Improved treatment options for iron overload patients.
- * Potential to prevent organ damage and improve cardiac and liver function.